Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Janux Therapeutics Inc
JANXCurrent price
48.32 USD
-0.9 USD (-1.83%)
Last closed
49.46 USD
Company
www.januxrx.com
ISIN
US47103J1051
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 608 746 496 USD
Yield for 12 month
+401.24 %
1Y
3Y
5Y
10Y
15Y
JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. Address: 10955 Vista Sorrento Parkway, San Diego, CA, United States, 92130
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
67.5 USDP/E ratio
–Dividend Yield
–Current Year
+8 083 000 USD
Last Year
+8 612 000 USD
Current Quarter
+8 897 000 USD
Last Quarter
+1 252 000 USD
Current Year
+6 128 000 USD
Last Year
+8 612 000 USD
Current Quarter
+8 391 000 USD
Last Quarter
+720 000 USD
Key Figures JANX
1 year
3 years
5 years
10 years
EBITDA
-63 864 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-7.98 %
PEG Ratio
–
Return On Equity TTM
-9.2 %
Wall Street Target Price
67.5 USD
Revenue TTM
15 127 000 USD
Book Value
12.61 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
741.7 %
Dividend Yield
–
Gross Profit TTM
-44 829 000 USD
Earnings per share
-0.88 USD
Diluted Eps TTM
-0.88 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-291.17 %
Dividend Analytics JANX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History JANX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation JANX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
131.3065
Price Sales TTM
172.4563
Enterprise Value EBITDA
-33.7973
Price Book MRQ
3.9666
Financials JANX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators JANX
For 52 weeks
5.65 USD
65.6 USD
50 Day MA
42.64 USD
Shares Short Prior Month
3 251 084
200 Day MA
33.83 USD
Short Ratio
6.61
Shares Short
3 315 464
Short Percent
12.56 %
BeatStart